Aldeyra Therapeutics, Inc. 8-K

What Happened
Aldeyra Therapeutics announced on March 17, 2026 that it received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration regarding its New Drug Application (NDA) for reproxalap, an investigational treatment for dry eye disease. The company issued a press release to disclose the FDA action and furnished that release on Form 8-K under Item 7.01 (Regulation FD Disclosure).

Key Details

• Date of disclosure: March 17, 2026 (press release furnished as Exhibit 99.1 to the Form 8-K).
• Product/filing: Reproxalap NDA for the treatment of dry eye disease.
• Regulatory action: FDA issued a Complete Response Letter (CRL) — the application was not approved in its current form.
• Filing item: Disclosure reported under Item 7.01 (Regulation FD Disclosure) of the Form 8-K.

Why It Matters
A CRL means the FDA has identified issues that prevent approval of the NDA as submitted; this can delay potential approval, commercialization, and any related revenue timeline for reproxalap. The 8-K itself does not describe the CRL’s specific contents or Aldeyra’s planned next steps. Investors should watch for follow-up disclosures from Aldeyra (press releases, SEC filings) that describe the FDA’s concerns and the company’s response, which will be material to the program’s outlook.